

## CONTENTS

INTRODUCTION	1-5
<b>SECTION I</b>	<b>6-66</b>
1. INTRODUCTION	6
1.1. Cancer	6
1.2. Computer aided drug design	10
1.2.1. Protein crystallography & homology modeling	12
1.2.2. Molecular docking	14
1.2.3. Molecular simulation	15
1.2.4. Force field	16
1.2.5. Pharmacophore modeling	17
1.2.6. Virtual screening	18
1.2.7. Quantitative structure activity relationship	19
2. REVIEW OF LITERATURE	22
3. AIMS AND OBJECTIVES	32
4. RESULTS AND DISCUSSION	34
4.1. Identification of structural requirements for imidazo[1,2- <i>a</i> ]pyrazine derivatives as aurora A kinase inhibitors by using docking based conformation and systematic validation of the developed model	34
4.2. Development of 4D-QSAR model for the investigation of essential structural requirements for Benzo[ <i>e</i> ]pyrimido[5,4- <i>b</i> ][1,4]diazepin-6(11 <i>H</i> )-one derivatives as aurora A kinase inhibitors and the methodical validation of the developed model	47
5. EXPERIMENTAL	58
5.1. Identification of structural requirements for imidazo[1,2- <i>a</i> ]pyrazine derivatives as aurora A kinase inhibitors by using docking based conformation and systematic validation of the developed model	58
5.2. Development of 4D-QSAR model for the investigation of essential Structural requirements for Benzo[ <i>e</i> ]pyrimido[5,4- <i>b</i> ][1,4]diazepin-6(11 <i>H</i> )-one	

derivatives as aurora A kinase inhibitors and the methodical validation of the developed model	60
5.3. Additional validation parameters used to validate the developed model	61
6. CONCLUSION	65
<b>SECTION II</b>	<b>67-160</b>
1. INTRODUCTION	67
1.1. Alzheimer's disease	67
1.2. Pathophysiology	68
2. REVIEW OF LITERATURE	73
3. AIMS AND OBJECTIVES	81
4. RESULTS AND DISCUSSION	83
4.1. Chemical Studies	83
4.1.1. Series I: Synthesis of isoalloxazine derivatives (10-Substituted-benzo[g]pteridine-2,4(3 <i>H</i> ,10 <i>H</i> )-diones)	83
4.1.2. Series II: 1,2,4-Triazino[5,6- <i>b</i> ]indole-3-thiones (3-(Substituted thio)-5 <i>H</i> -[1,2,4]triazino [5,6- <i>b</i> ]indole) derivatives	88
4.1.3. Series III: Synthesis of 5-Substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indole-3-thiol derivatives	91
4.1.4. Series IV: Synthesis of 6-Substituted-6 <i>H</i> -indolo[2,3- <i>b</i> ]quinoxaline derivatives	94
4.1.5. Series V: Synthesis of 5-Substituted 5 <i>H</i> -indolo[2,3- <i>b</i> ]quinoxaline derivatives	98
4.2. Pharmacological evaluation	101
4.2.1. Pharmacological evaluation of Isoalloxazine derivatives (Series I) as anti-Alzheimer's agents	101
4.2.2. Pharmacological evaluation of triazinoindole derivatives (Series II and Series III) as anti-Alzheimer agents	105

4.2.3. Pharmacological evaluation of 6-substituted 6 <i>H</i> -indolo[2,3- <i>b</i> ]quinoxaline derivatives (Series IV) and 5-substituted 5 <i>H</i> -indolo[2,3- <i>b</i> ]quinoxaline derivatives (Series V) as anti-Alzheimer's agents	107
4.3. Docking studies	108
5. EXPERIMENTAL	117
5.1. Chemical work	117
5.1.1. Synthesis of isoalloxazine derivatives (10-substituted benzo[ <i>g</i> ]pteridine-2,4(3 <i>H</i> ,10 <i>H</i> )-dione) (Series I)	117
5.1.2. Synthesis of 1,2,4-triazino[5,6- <i>b</i> ]indole-3-thione (3-(Substitutedthio)-5 <i>H</i> -[1,2,4]triazino [5,6 - <i>b</i> ]indole) derivatives (series II)	129
5.1.3: Synthesis of 5-substituted-5 <i>H</i> -[1,2,4]triazino [5,6- <i>b</i> ]indole-3-thiol derivatives (series III)	135
5.1.4. Synthesis of 6-substituted-6 <i>H</i> -indolo[2,3- <i>b</i> ]quinoxaline derivatives (series IV)	142
5.1.5. Synthesis of 5-substituted-5 <i>H</i> -indolo[2,3- <i>b</i> ]quinoxaline derivatives (series V)	147
5.2. Pharmacological evaluation	151
5.2.1. Cholinesterase inhibition assay (Ellman's method)	151
5.2.2. <i>h</i> AChE induced A $\beta$ <sub>1-42</sub> aggregation inhibition assay (Thioflavin-T assay)	152
5.2.3. Congo red assay	153
5.2.4. Cytotoxicity studies	153
5.3. Docking studies	154
6. CONCLUSION	155

<b>SECTION III</b>	<b>161-185</b>
1. INTRODUCTION	161
1.1. Atherosclerosis	161
1.2. Acyl Coenzyme A: Cholesterol O-Acyl Transferase (ACAT)	163
2. REVIEW OF LITERATURE	166
3. AIMS AND OBJECTIVES	169
4. RESULTS AND DISCUSSION	170
5. EXPERIMENTAL	180
5.1. Development of models of ACAT receptors	180
5.2. Docking studies and development of pharmacophore based 3D-QSAR model	183
6. CONCLUSION	185
<b>REFERENCES</b>	<b>186-201</b>